• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

    4.195 -0.115 (-2.67%)
    Delayed Quote Updated: 2:36 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 639,412
    Open 4.280
    Bid (Size) 4.190 (700)
    Ask (Size) 4.200 (900)
    Prev. Close 4.310
    Today's Range 4.130 - 4.310
    52wk Range 2.740 - 8.590
    Shares Outstanding 93,500,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    3 Reasons MYGN is Risky and 1 Stock to Buy Instead
    Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&... 
    Via StockStory
    Topics Bankruptcy
    News headline image
    Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
    Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
    Via StockStory
    Topics Artificial Intelligence

    Performance

    YTD
    -31.7%
    -31.7%
    1 Month
    +30.3%
    +30.3%
    3 Month
    -30.1%
    -30.1%
    6 Month
    -8.6%
    -8.6%
    1 Year
    -42.0%
    -42.0%

    More News

    Read More
    News headline image
    1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
    Via StockStory
    News headline image
    Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    2 Unprofitable Stocks to Research Further and 1 We Find Risky
    Via StockStory
    News headline image
    Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter
    Via StockStory
    Topics Economy
    News headline image
    Why Myriad Genetics (MYGN) Stock Is Down Today
    Via StockStory
    News headline image
    Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Myriad Genetics and Moderna Shares Plummet, What You Need To Know
    Via StockStory
    News headline image
    1 Small-Cap Stock with Promising Prospects and 2 That Underwhelm
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    3 Healthcare Stocks with Open Questions
    Via StockStory
    News headline image
    MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Myriad Genetics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Artificial Intelligence Earnings
    Top movers in Friday's session ↗
    Via Chartmill
    News headline image
    Why Myriad Genetics (MYGN) Shares Are Falling Today
    Via StockStory
    Topics Artificial Intelligence
    Top stock movements in today's session. ↗
    Via Chartmill
    Gapping stocks in Friday's session ↗
    Via Chartmill
    Friday's pre-market session: top gainers and losers ↗
    Via Chartmill

    Frequently Asked Questions

    Is Myriad Genetics, Inc. - Common Stock publicly traded?
    Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
    What exchange does Myriad Genetics, Inc. - Common Stock trade on?
    Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
    The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
    What is the current price of Myriad Genetics, Inc. - Common Stock?
    The current price of Myriad Genetics, Inc. - Common Stock is 4.195
    When was Myriad Genetics, Inc. - Common Stock last traded?
    The last trade of Myriad Genetics, Inc. - Common Stock was at 10/01/26 02:36 PM ET
    What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
    The market capitalization of Myriad Genetics, Inc. - Common Stock is 392.23M
    How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
    Myriad Genetics, Inc. - Common Stock has 392M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.